ATHE / Alterity Therapeutics Limited - Depositary Receipt (Common Stock) - Depositi SEC, Relazione annuale, dichiarazione di delega

Share Consolidation and ASX Code ‒ Alterity shares to trade under the temporary ticker of “ATHDA” until 12 June ‒

Exhibit 99.1 Share Consolidation and ASX Code ‒ Alterity shares to trade under the temporary ticker of “ATHDA” until 12 June ‒ MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 June 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, advises that, further to sh

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2026 Alterity Therapeutics Limited (Name of Registr

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2026 Alterity Therapeutics Limited (Name of Registrant) Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regis

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2026 Alterity Therapeutics Limited (Name of Registr

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2026 Alterity Therapeutics Limited (Name of Registrant) Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regis

Change of Registered Office Address

Exhibit 99.1 Change of Registered Office Address MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 3 June 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) wishes to advise that for the purposes of ASX Listing Rule 3.14, the Company’s registered office address has changed to the below, effective 3 June 2026. Address: Level 15, 500 Collins Street Melbourne VIC 3000. Thi

Results of 2026 Extraordinary General Meeting

Exhibit 99.1 Results of 2026 Extraordinary General Meeting MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 29 May 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that in accordance with ASX Listing rule 3.13.2 and Section 251AA of the Corpor

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2026 Alterity Therapeutics Limited (Name of Registra

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2026 Alterity Therapeutics Limited (Name of Registra

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regist

Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy – Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – – End-of-Phase 2 FDA

Exhibit 99.1 Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy – Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – – End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm path forward for Phase 3 – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 19 May 2026: Alterity

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2026 Alterity Therapeutics Limited (Name of Registra

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regist

EXHIBIT 99.1

Exhibit 99.1

Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy – Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron

Exhibit 99.1 Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy – Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in patients with Multiple System Atrophy (MSA) – – Findings su

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2026 Alterity Therapeutics Limited (Name of Registra

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regist

Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026

Exhibit 99.1 Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026 MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 7 May 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the C

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2026 Alterity Therapeutics Limited (Name of Registra

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regist

Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update

Exhibit 99.1 Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update Highlights ● Aligned with the FDA in two Positive Type C meetings supporting key elements of the planned Phase 3 program for ATH434 in MSA ● Advancing ATH434 toward pivotal Phase 3 program; on track for End-of-Phase 2 FDA meeting mid-year 2026 ● Late breaking platform presentation at American Academy of Neurology annu

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

EXHIBIT 99.1

Exhibit 99.1

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

Upcoming General Meeting of Shareholders

Exhibit 99.1 All Registry communications to: Automic Group GPO Box 5193 Sydney NSW 2001 Telephone (free call within Australia): 1300 288 664 ASX Code: ATH 29 April 2026 Upcoming General Meeting of Shareholders Dear Shareholder, Alterity Therapeutics Limited, ACN 080 699 065 (ASX: ATH or “the Company”), advises that a General Meeting will be held online at investor.automic.com.au on Friday, 29 May

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy – Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development progra

Exhibit 99.1 Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy – Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program – – Positive feedback supports readiness for Phase 3 initiation with manufacturing scale-up progressing in parallel – – End-of-Phase 2

EXHIBIT 99.1

Exhibit 99.1

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology - ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale

Exhibit 99.1 Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology - ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale - - Effects seen on both daily function and neurological examination, consistent with previously reported activity on modified UMSARS Par

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

Appendix 3X Initial Director’s Interest Notice

Exhibit 99.1 Appendix 3X Initial Director’s Interest Notice Rule 3.19A.1 Appendix 3X Initial Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity Alterity Therapeutics Limited ABN 37 080 699 065 We (the entity) give AS

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

EXHIBIT 99.1

Exhibit 99.1

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

EXHIBIT 99.1

Exhibit 99.1

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors

Exhibit 99.1 Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 17 April 2026: Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the ap

Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting

Exhibit 99.1 Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 16 April 2026: Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy

Exhibit 99.1 Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 15 April 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announce

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

EXHIBIT 99.1

Exhibit 99.1

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2026 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program – Alignment reached on key elements of ATH434 Phase 3 development program –

Exhibit 99.1 Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program – Alignment reached on key elements of ATH434 Phase 3 development program – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 30 March 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying tr

EXHIBIT 99.1

Exhibit 99.1

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2026 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2026 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

Announcement Summary

Exhibit 99.1 Appendix 3B - Proposed issue of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement 19/3/2026 The Proposed issue is: A placement or other type of issue Total number of +securities proposed to be issued for a placement or other type of issue ASX +security code +Security description Maximum Number of +sec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2026 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

UNMARKETABLE PARCEL SALE FACILITY

Exhibit 99.1 13 March 2026 ASX Announcement UNMARKETABLE PARCEL SALE FACILITY Alterity Therapeutics Limited (ASX:ATH) (ATH or the Company) announced today that it has established an opt-out unmarketable parcel sale facility (Facility) for shareholders who hold less than $500 worth of fully paid ordinary shares in the Company (Unmarketable Parcel). The Company has established the Facility for the f

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2026 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit

Exhibit 99.1 Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 9 March 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive

Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor - Neurology and Movement Disorder Specialist Adds Deep Clinical and Development Expertise –

Exhibit 99.1 Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor - Neurology and Movement Disorder Specialist Adds Deep Clinical and Development Expertise – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 March 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying tre

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2026 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

Attributable to owners of

Exhibit 99.1 Table of Contents Table of Contents Alterity Therapeutics Limited Appendix 4D Half-year ended 31 December 2025 Name of entity: Alterity Therapeutics Limited ABN: 37 080 699 065 Half-year ended: 31 December 2025 Previous period: 31 December 2024 Results for announcement to the market A$ Revenue from ordinary activities Up 717% to $909,750 Net loss after tax (from ordinary activities) f

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2026 Alterity Therapeutics Limited (Name of Reg

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the r

Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced −

Exhibit 99.1 30 January 2026 Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights ● Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter. ● Regulatory planning activities adva

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Alterity Therapeutics Limited (Name of Regi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the re

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Alterity Therapeutics Limited (Name of Regi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the re

Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026

Exhibit 99.1 Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026 MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 21 January 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to sharehold

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 15, 2026 Alterity Therapeutics Limited (Name of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 15, 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether th

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

Exhibit 99.1 Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Date of this announcement Thursday January 15, 2026 The +securities the subject of this notification are: +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Total number of +securi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 15, 2026 Alterity Therapeutics Limited (Name of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 15, 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether th

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

Exhibit 99.1 Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Date of this announcement Thursday January 15, 2026 The +securities the subject of this notification are: +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Total number of +securi

January 2026 Corporate Presentation Forward looking statements 2 This presentation may contain some statements that may be considered “Forward - Looking Statements”, within the meaning of the US Securities Laws. Thus, any forward - looking statement

Exhibit 99.1 January 2026 Corporate Presentation Forward looking statements 2 This presentation may contain some statements that may be considered “Forward - Looking Statements”, within the meaning of the US Securities Laws. Thus, any forward - looking statement relating to financial projections or other statements relating to the Company’s plans, objectives, expectations or intentions involve ris

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 13, 2026 Alterity Therapeutics Limited (Name of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 13, 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether th

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 7, 2026 Alterity Therapeutics Limited (Name of R

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 7, 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 07, 2026 Alterity Therapeutics Limited (Name of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 07, 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether th

Announcement Summary

Exhibit 99.1 Appendix 3H - Notification of cessation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Wednesday January 07, 2026 Details of +securities that have ceased ASX +security code Security description Number of +securities that have ceased The +securities have ceased due to Date of cessation ATHAAD OPT

Appendix 3Y Change of Director’s Interest Notice

Exhibit 99.1 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Alterity Therapeutics Limited ABN 37 080 699 065 We

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 24, 2025 Alterity Therapeutics Limited (Name of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 24, 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether t

Appendix 3X Initial Director’s Interest Notice

Exhibit 99.1 Appendix 3X Initial Director’s Interest Notice Rule 3.19A.1 Appendix 3X Initial Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity Alterity Therapeutics Limited ABN 37 080 699 065 We (the entity) give AS

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 24, 2025 Alterity Therapeutics Limited (Name of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 24, 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether t

Appendix 3Z Final Director’s Interest Notice

Exhibit 99.1 Appendix 3Z Final Director’s Interest Notice Rule 3.19A.3 Appendix 3Z Final Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX’s property and may be made public. Introduced 30/9/2001. Name of entity Alterity Therapeutics Limited ABN 37 080 699 065 We (the entity) give ASX t

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 24, 2025 Alterity Therapeutics Limited (Name of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 24, 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether t

Appendix 3Z Final Director’s Interest Notice

Exhibit 99.1 Appendix 3Z Final Director’s Interest Notice Rule 3.19A.3 Appendix 3Z Final Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX’s property and may be made public. Introduced 30/9/2001. Name of entity Alterity Therapeutics Limited ABN 37 080 699 065 We (the entity) give ASX t

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 24, 2025 Alterity Therapeutics Limited (Name of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 24, 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether t

Appendix 3X Initial Director’s Interest Notice

Exhibit 99.1 Appendix 3X Initial Director’s Interest Notice Rule 3.19A.1 Appendix 3X Initial Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX’s property and may be made public. Introduced 30/9/2001. Name of entity Alterity Therapeutics Limited ABN 37 080 699 065 We (the entity) give A

Alterity Therapeutics Announces Board Changes to Support the Next Phase of Growth

Exhibit 99.1 ASX ANNOUNCEMENT 21 November 2025 Alterity Therapeutics Announces Board Changes to Support the Next Phase of Growth Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) announces a series of Board changes ahead of its Annual General Meeting of Shareholders on Friday 21st November, designed to align with the Company’s next phase of growth

Chairman’s Address 2025 Annual General Meeting

Exhibit 99.1 Chairman’s Address 2025 Annual General Meeting Good morning, everyone. Thank you for joining us here in Melbourne for Alterity Therapeutics’ Annual General Meeting. Standing before you today is both a privilege and a poignant moment, as this marks my final AGM as Chairman after more than two decades guiding the company’s ambitions and growth. When I founded this company, originally kn

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 21, 2025 Alterity Therapeutics Limited (Name of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 21, 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether t

Results of 2025 Annual General Meeting

Exhibit 99.1 Results of 2025 Annual General Meeting MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 21 November 2025: In accordance with ASX Listing rule 3.13.2 and Section 251AA of the Corporations Act 2001 (Cth), the attached information is provided in relation to the resolutions passed by the shareholders of Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) at i

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 21, 2025 Alterity Therapeutics Limited (Name of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 21, 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether t

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 21, 2025 Alterity Therapeutics Limited (Name of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 21, 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether t

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 21, 2025 Alterity Therapeutics Limited (Name of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 21, 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether t

CEO’s presentation Dr David Stamler 21 November 2025 Forward looking statements 2 This presentation may contain some statements that may be considered “Forward - Looking Statements”, within the meaning of the US Securities Laws. Thus, any forward - l

Exhibit 99.1 CEO’s presentation Dr David Stamler 21 November 2025 Forward looking statements 2 This presentation may contain some statements that may be considered “Forward - Looking Statements”, within the meaning of the US Securities Laws. Thus, any forward - looking statement relating to financial projections or other statements relating to the Company’s plans, objectives, expectations or inten

Disclosure under Takeovers Panel Guidance Note 20: Equity Derivatives

Exhibit 99.1 ASX ANNOUNCEMENT 13 November 2025 Disclosure under Takeovers Panel Guidance Note 20: Equity Derivatives Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) (“the Company”) advises that it has received the attached notice from Regal Funds Management Asia Pte Limited which was provided to the Company pursuant to the Australian Takeovers Panel Guidance Note 20 – Equity

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 13, 2025 Alterity Therapeutics Limited (Name of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 13, 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether t

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

Exhibit 99.1 Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 12 November 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Execut

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 12, 2025 Alterity Therapeutics Limited (Name of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 12, 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether t

Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System – Data highlights symptom stability and enhanced efficacy signals

Exhibit 99.1 Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System – Data highlights symptom stability and enhanced efficacy signals in higher dose group – – Analysis offers valuable insights to guide ongoing development and planning of Phase 3 – MELBOURNE, AUSTRALIA AN

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 10, 2025 Alterity Therapeutics Limited (Name of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 10, 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether t

Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

Exhibit 99.1 Appendix 4C – Q1 FY26 Quarterly Cash Flow Report Highlights ● New analysis of ATH434-201 double blind trial strengthens efficacy signal at high dose level ● Positive data from ATH434-202 open-label trial demonstrates similar treatment effect in advanced MSA as observed in earlier stage patients in double-blind study ● Independent commercial assessment indicates USD $2.4 billion dollar

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 30, 2025 Alterity Therapeutics Limited (Name of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 30, 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether th

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 21, 2025 Alterity Therapeutics Limited (Name of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 21, 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether th

ALTERITY THERAPEUTICS LIMITED (“the Company”) ABN 37 080 699 065

Exhibit 99.1 ALTERITY THERAPEUTICS LIMITED (“the Company”) ABN 37 080 699 065 21 October 2025 ALTERITY THERAPEUTICS LIMITED ANNUAL GENERAL MEETING – NOTICE AND PROXY FORM Dear Shareholders 2025 ANNUAL GENERAL MEETING The Company’s annual general meeting is scheduled to be held at the offices of Deloitte Australia, Level 30, 477 Collins Street, Melbourne, VIC 3000 on Friday, 21 November 2025 at 11:

Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder

Exhibit 99.1 Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder To Company Name/Scheme Alterity Therapeutics ltd (ATH) ACN/ARSN 080 699 065 1. Details of substantial holder (1) Name Regal Funds Management Pty Limited and its associates (see Annexure 1) ACN/ARSN (if applicable) - There was a change in the interests of the substantial holder on 10/10/2025

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 14, 2025 Alterity Therapeutics Limited (Name of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 14, 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether th

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 9 2025 Alterity Therapeutics Limited (Name of Re

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 9 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders – Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension – – New

Exhibit 99.1 Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders – Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension – – New analysis increases overall confidence in the Phase 2 trial results – – State-of-the-art neuroimaging and biomarker analysis advance unde

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2 2025 Alterity Therapeutics Limited (Name of Re

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders – Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentation

Exhibit 99.1 Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders – Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 2 October 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Comp

DATE OF AGM AND CLOSING DATE FOR DIRECTOR NOMINATIONS

Exhibit 99.1 23 September 2025 ASX Announcement DATE OF AGM AND CLOSING DATE FOR DIRECTOR NOMINATIONS Alterity Therapeutics Limited (ASX:ATH, NASDAQ:ATHE) (Alterity or the Company) advises that, in accordance with ASX Listing Rule 3.13.1, its next Annual General Meeting (AGM) will be held at 11.00am (AEDT) on Friday 21 November 2025. In addition, the closing date for the receipt of nominations fro

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Re

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the

Appendix 3Y Change of Director’s Interest Notice

Exhibit 99.1 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Alterity Therapeutics Limited ABN 37 080 699 065 We

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Re

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the

Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder To Company Name/Scheme Alterity Therapeutics Limited ACN/ARSN 080 699 065 1. Details of substantial holder (1) Name The Bank of New York Mellon Corporatio

Exhibit 99.1 Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder To Company Name/Scheme Alterity Therapeutics Limited ACN/ARSN 080 699 065 1. Details of substantial holder (1) Name The Bank of New York Mellon Corporation (BNYMC) and each Group Entity listed in Annexure A (Group Entity),(together BNYMC Group) ACN/ARSN (if applicable) There was a change in

Announcement Summary

Exhibit 99.1 Appendix 3H - Notification of cessation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Wednesday September 17, 2025 Details of +securities that have ceased ASX +security code Security description Number of +securities that have ceased The +securities have ceased due to Date of cessation ATHAAB O

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Re

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Re

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the

Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting ATH434 demonstrated clinically meaningful efficacy in modifying disease progression and was well tolerated at both 50 and 75 mg doses

Exhibit 99.1 Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting ATH434 demonstrated clinically meaningful efficacy in modifying disease progression and was well tolerated at both 50 and 75 mg doses MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 15 September 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Re

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the

Announcement Summary

Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Monday September 15, 2025 The +securities to be quoted are: +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Total number of +securities to be qu

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Re

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Re

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the

Notice Under Section 708A(5)(e) of the Corporations Act

Exhibit 99.1 ASX ANNOUNCEMENT 15 September 2025 Notice Under Section 708A(5)(e) of the Corporations Act This notice is given by Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act). Details of securities issued Type: Shares Class/Description: Fully paid ordinary shares AS

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Re

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Re

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

Exhibit 99.1 Alterity Therapeutics Raises A$20.0 million in Strategic Placement MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 8 September 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received binding commitments for a capital rai

Announcement Summary

Exhibit 99.1 Appendix 3B - Proposed issue of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement 8/9/2025 The Proposed issue is: A placement or other type of issue Total number of +securities proposed to be issued for a placement or other type of issue ASX +security code +Security description Maximum number of +secu

Alterity Therapeutics Limited Suite 4, Level 14, 350 Collins Street, Melbourne, VIC 3000 Australia T: +61 (0)3 9349 4906 | www.alteritytherapeutics.com

Exhibit 99.1 Market Announcement 4 September 2025 Alterity Therapeutics Limited (ASX: ATH) – Trading Halt Trading in the securities of Alterity Therapeutics Limited (‘ATH’) will be halted at the request of ATH, pending the release of an announcement by ATH. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of: ● the commencement of normal trading on Monday,

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Re

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Re

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the

Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations

Exhibit 99.1 Rules 4.7.3 and 4.10.3 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Alterity Therapeutics Ltd ABN/ARBN Financial year ended: 37 080 699 065 30 June 2025 Our corporate governance statement1 for the period above can be found at:2 ☐ These pages of our annual report: ☒ This URL on our website: https://alteritytherapeutics.com/in

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Alterity Therapeutics Limited (Name of Regis

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the reg

Alterity Therapeutics Filed Form 20-F and XBRL data with the SEC

Exhibit 99.1 Alterity Therapeutics Filed Form 20-F and XBRL data with the SEC MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 2 September 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has filed its Annual Report on Form 20-F contai

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Re

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the

Alterity Therapeutics to Present at the Biotech Showcase

Exhibit 99.1 Alterity Therapeutics to Present at the Biotech Showcase MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 1 September 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity,

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Alterity Therapeutics Limited (the “Company”) on Form 20- F for the year ended June 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David A. Stamler, Chief Executive Officer of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193

CERTIFICATION OF CHIEF EXECUTIVE OFFICER Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended

Exhibit 12.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended I, David A, Stamler, certify that: 1. I have reviewed this annual report on Form 20-F of Alterity Therapeutics Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make

CERTIFICATION OF CHIEF FINANCIAL OFFICER Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended

Exhibit 12.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended I, Abby Macnish Niven, certify that: 1. I have reviewed this annual report on Form 20-F of Alterity Therapeutics Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to ma

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Alterity Therapeutics Limited (the “Company”) on Form 20-F for the year ended June 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Abby Macnish Niven, Chief Financial Officer o

This page is required for Australian Disclosure Requirements and has been intentionally left blank.

Exhibit 15.2 This page is required for Australian Disclosure Requirements and has been intentionally left blank.

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-228671, 333-248980, 333-251073) and Form F-3 (No. 333-274816) of Alterity Therapeutics Limited of our report dated August 29, 2025 relating to the financial statements, which appears in this Form 20-F. /s/ PricewaterhouseCoop

Announcement Summary

Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Friday August 22, 2025 The +securities to be quoted are: +Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted Total number of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Alterity Therapeutics Limited (Name of Regis

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the reg

Announcement Summary

Exhibit 99.1 Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Date of this announcement Friday August 15, 2025 The +securities the subject of this notification are: +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Total number of +securitie

Announcement Summary

Exhibit 99.1 Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Date of this announcement Friday August 15, 2025 The +securities the subject of this notification are: +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Total number of +securitie

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Alterity Therapeutics Limited (Name of Regis

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the reg

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Alterity Therapeutics Limited (Name of Regis

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the reg

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Alterity Therapeutics Limited (Name of Regis

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the reg

Alterity Therapeutics Limited Suite4, Level 14, 350 Collins Street, Melbourne, VIC 3000 Australia T: +61 (0)3 9349 4906 | WWW.alteritytherapeutics.com

Exhibit 99.1 Market Announcement 4 August 2025 Attached for the information of the market are ASX’s query letters to Alterity Therapeutics Limited (ASX:ATH) dated 24 July 2025 and 30 July 2025 and ATH’s responses 28 July 2025 and 3 August 2025. 4 August 2025 Market Announcement 1/1 ASX Limited ASX Customer Service Centre 131 279 | asx.com.au 24 July 2025 Reference: ODIN111104 Ms Abby Macnish Compa

July 2025 Corporate Presentation Forward looking statements 2 This presentation may contain some statements that may be considered “Forward - Looking Statements”, within the meaning of the US Securities Laws. Thus, any forward - looking statement rel

Exhibit 99.1 July 2025 Corporate Presentation Forward looking statements 2 This presentation may contain some statements that may be considered “Forward - Looking Statements”, within the meaning of the US Securities Laws. Thus, any forward - looking statement relating to financial projections or other statements relating to the Company’s plans, objectives, expectations or intentions involve risks

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Alterity Therapeutics Limited (Name of Registr

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regis

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Alterity Therapeutics Limited (Name of Registr

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regis

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

Exhibit 99.1 Appendix 4C – Q4 FY25 Quarterly Cash Flow Report Highlights ● Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA) ● Reported positive topline data from open-label Phase 2 clinical trial of ATH434 in MSA ● Presented additional analyses from the ATH434-201 trial demonstrating continued robust efficacy for the treatment of MSA ● Cash balance on 30 Ju

Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder

Exhibit 99.1 604 Page 1 of 2 15 July 2001 Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder To Company Name/Scheme Alterity Therapeutics Limited ACN/ARSN 080 699 065 1. Details of substantial holder (1) Name The Bank of New York Mellon Corporation (BNYMC) and each Group Entity listed in Annexure A (Group Entity), (together BNYMC Group) ACN/ARSN (if app

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy – ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms – – Ne

Exhibit 99.1 Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy – ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms – – Neuroimaging Biomarkers Showed Target Engagement and Slowed Brain Atrophy – – ATH434 was Well-Tolerated with Favorable Safety Profile – – D

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Alterity Therapeutics Limited (Name of Registr

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regis

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Alterity Therapeutics Limited (Name of Registr

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regis

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study – Peer-reviewed publication in Annals of Clinical and Translational Neurology highlights the use of the MSA Atrophy Index developed to diagnose a

Exhibit 99.1 Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study – Peer-reviewed publication in Annals of Clinical and Translational Neurology highlights the use of the MSA Atrophy Index developed to diagnose and track disease progression in Multiple System Atrophy – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 24 July 2025: Alterity Therapeuti

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Alterity Therapeutics Limited (Name of Registr

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regis

Announcement Summary

Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Monday July 21, 2025 The +securities to be quoted are: +Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted Total number of +

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Alterity Therapeutics Limited (Name of Registr

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regis

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Alterity Therapeutics Limited (Name of Registr

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regis

Announcement Summary

Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Thursday July 17, 2025 The +securities to be quoted are: +Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted Total number of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Alterity Therapeutics Limited (Name of Registr

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regis

Alterity Therapeutics Limited Level 3, 460 Bourke Street, Melbourne, VIC 3000 Australia T: +61 (0)3 9349 4906 | WWW.alteritytherapeutics.com

Exhibit 99.1 14 July 2025 By email: [email protected] Melissa Kostopoulos Adviser, Listings Compliance (Melbourne) ASX Limited Dear Melissa Response to Price Query We refer to your letter dated 11 July 2025 wherein the ASX notes an increase in share price of Alterity Therapeutics Limited (ASX: ATH) (Company) securities between close of trade on 10 July 2025 to intra-day trading on 11

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Alterity Therapeutics Limited (Name of Registr

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regis

Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder

Exhibit 99.1 604 Page 1 of 2 15 July 2001 Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder To Company Name/Scheme Alterity Therapeutics Limited ACN/ARSN 080 699 065 1. Details of substantial holder (1) Name The Bank of New York Mellon Corporation (BNYMC) and each Group Entity listed in Annexure A (Group Entity), (together BNYMC Group) ACN/ARSN (if app

Announcement Summary

Exhibit 99.1 Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Date of this announcement Thursday July 03, 2025 The +securities the subject of this notification are: +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Total number of +securitie

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Alterity Therapeutics Limited (Name of Registr

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regis

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Alterity Therapeutics Limited (Name of Registr

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regis

Announcement Summary

Exhibit 99.1 Appendix 3H - Notification of cessation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Monday June 30, 2025 Details of +securities that have ceased ASX +security code Security description Number of +securities that have ceased The +securities have ceased due to Date of cessation ATHAAE OPTION EX

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Alterity Therapeutics Limited (Name of Registr

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regis

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

Exhibit 99.1 Alterity Therapeutics to Provide Corporate Update in Fireside Chat MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 23 June 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alte

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Alterity Therapeutics Limited (Name of Registra

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regist

Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder

Exhibit 99.1 604 Page 1 of 2 15 July 2001 Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder To Company Name/Scheme Alterity Therapeutics Limited ACN/ARSN 080 699 065 1. Details of substantial holder (1) Name The Bank of New York Mellon Corporation (BNYMC) and each Group Entity listed in Annexure A (Group Entity), (together BNYMC Group) ACN/ARSN (if app

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Alterity Therapeutics Limited (Name of Registra

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regist

Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder

Exhibit 99.1 604 Page 1 of 2 15 July 2001 Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder To Company Name/Scheme Alterity Therapeutics Limited ACN/ARSN 080 699 065 1. Details of substantial holder (1) Name The Bank of New York Mellon Corporation (BNYMC) and each Group Entity listed in Annexure A (Group Entity), (together BNYMC Group) ACN/ARSN (if app

Alterity Therapeutics Prominently Featured at the International MSA Congress – ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints – – MSA Atrophy Index (MSAai) enhances MSA diagnosis and monitoring – – bioM

Exhibit 99.1 Alterity Therapeutics Prominently Featured at the International MSA Congress – ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints – – MSA Atrophy Index (MSAai) enhances MSA diagnosis and monitoring – – bioMUSE Study shows higher α- synuclein concentration is associated with greater burden of orthostatic symptoms – MELBOURNE, AUSTRALIA AND SA

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Alterity Therapeutics Limited (Name of Registra

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regist

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress –ATH434 Phase 2 Data to be Presented at Opening Plenary Session –

Exhibit 99.1 Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress –ATH434 Phase 2 Data to be Presented at Opening Plenary Session – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 7 May 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Alterity Therapeutics Limited (Name of Registra

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regist

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy – Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA –

Exhibit 99.1 Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy – Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 5 May 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated t

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Alterity Therapeutics Limited (Name of Registra

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

 Exhibit 99.1 Appendix 4C – Q3 FY25 Quarterly Cash Flow Report Highlights ● Reported positive topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) led by robust clinical efficacy ● Phase 2 data featured in an oral presentation at the American Academy of Neurology Annual Meeting ● ATH434-202 open-label trial in advanced MSA completed in March

Appendix 3Y Change of Director’s Interest Notice

Exhibit 99.1 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Alterity Therapeutics Limited ABN 37 080 699 065 We

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Exhibit 99.1 Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 28 April 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

As at Date: 16 - Apr - 2025 Top Holders Grouped Report Alterity Therapeutics Limited Security Class(es): ATHOPTWC25 - LISTED OPT EXP 26/02/2027 @ $0.028 Display Top: 20 ABN: 27 152 260 814 Level 5, 126 Phillip Street, Sydney NSW 2000 GPO Box 5193, Sy

Exhibit 99.1 As at Date: 16 - Apr - 2025 Top Holders Grouped Report Alterity Therapeutics Limited Security Class(es): ATHOPTWC25 - LISTED OPT EXP 26/02/2027 @ $0.028 Display Top: 20 ABN: 27 152 260 814 Level 5, 126 Phillip Street, Sydney NSW 2000 GPO Box 5193, Sydney NSW 2000 1300 288 664 (within australia) +61 2 9698 5414 (international) [email protected] www.automic.com.au % IC Holding Holder

Announcement Summary

Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Tuesday April 22, 2025 The +securities to be quoted are: Other Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue. New cl

David Stamler, MD CEO April 2025 Forward Looking Statements This presentation may contain some statements that may be considered “Forward - Looking Statements”, within the meaning of the US Securities Laws . Thus, any forward - looking statement rela

Exhibit 99.1 David Stamler, MD CEO April 2025 Forward Looking Statements This presentation may contain some statements that may be considered “Forward - Looking Statements”, within the meaning of the US Securities Laws . Thus, any forward - looking statement relating to financial projections or other statements relating to the Company’s plans, objectives, expectations or intentions involve risks a

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

ALTERITY THERAPEUTICS LIMITED [ACN 080 699 065] (“the Company”) OPTIONS PROSPECTUS

Exhibit 99.1 ALTERITY THERAPEUTICS LIMITED [ACN 080 699 065] (“the Company”) OPTIONS PROSPECTUS This prospectus (Prospectus) contains the following offers of options (New Options) (each with an exercise price of A$0.028 (2.8 Australian cents), expiry date of 26 February 2027 and which, upon exercise, entitle the holder to one fully paid ordinary share in the capital of the Company (Share): ● 1,212

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting – Clinically Meaningful Efficacy Observed on Multiple Assessments – – Confirmed Target En

Exhibit 99.1 Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting – Clinically Meaningful Efficacy Observed on Multiple Assessments – – Confirmed Target Engagement with Reduced Iron Signal in MSA Affected Brain Regions – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 10 April 2025: Alterity T

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

Topline Data from a Randomized, Double Blind, Placebo Controlled Phase 2 Study of ATH434 in MSA David Stamler 1 , Cynthia Wong 1 , Paula Trujillo 2 , Margaret Bradbury 1 , Christine Lucas 1 and Daniel Claassen 2 1 Alterity Therapeutics, Newark, CA, U

Exhibit 99.1 Topline Data from a Randomized, Double Blind, Placebo Controlled Phase 2 Study of ATH434 in MSA David Stamler 1 , Cynthia Wong 1 , Paula Trujillo 2 , Margaret Bradbury 1 , Christine Lucas 1 and Daniel Claassen 2 1 Alterity Therapeutics, Newark, CA, USA 2 Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA American Academy of Neurology Annual Meeting 2025

Appendix 3Y Change of Director’s Interest Notice

Exhibit 99.1 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Alterity Therapeutics Limited ABN 37 080 699 065 We

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

BECOMING A SUBSTANTIAL HOLDER

Exhibit 99.1

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

604 Page 1 of 2 15 July 2001 Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder Alterity Therapeutics Limited To Company Name/Scheme 080 699 065 ACN/ARSN 1. Details of substantial holder (1) The Bank of Ne

Exhibit 99.1 604 Page 1 of 2 15 July 2001 Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder Alterity Therapeutics Limited To Company Name/Scheme 080 699 065 ACN/ARSN 1. Details of substantial holder (1) The Bank of New York Mellon Corporation (BNYMC) and each Group Entity listed in Annexure A (Group Entity),(together BNYMC Group) Name ACN/ARSN (if appl

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

Announcement Summary

Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Monday April 07, 2025 The +securities to be quoted are: +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Total number of +securities to be quoted

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

Alterity Therapeutics Announces Completion of Placement

Exhibit 99.1 Alterity Therapeutics Announces Completion of Placement MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 7 April 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced completion of the second tranche of the two-tranche placement initia

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

Notice Under Section 708A(5)(e) of the Corporations Act

Exhibit 99.1 ASX ANNOUNCEMENT 07 April 2025 Notice Under Section 708A(5)(e) of the Corporations Act This notice is given by Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act). Details of securities issued Type: Shares Class/Description: Fully paid ordinary shares ASX Co

Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting

EX-99.1 2 ea023705301ex99-1alterity.htm ALTERITY TO DELIVER ORAL PRESENTATION OF ATH434 TRIAL AT AAN Exhibit 99.1 Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 3 April 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

GPO Box 5193, Sydney, NSW 2001

Exhibit 99.1 Disclosure of Proxy Votes Alterity Therapeutics Limited Extraordinary General Meeting Monday, 31 March 2025 GPO Box 5193, Sydney, NSW 2001 P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world) F +61 (0)2 8583 3040 E [email protected] ABN 27 152 260 814 In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy – ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders – – Topline Data Expected Mid-Year 2025 –

Exhibit 99.1 Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy – ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders – – Topline Data Expected Mid-Year 2025 – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 27 March 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotech

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

605 Page 1 of 2 Form 605 Corporations Act 2001 Section 671B Notice of ceasing to be a substantial holder To Company Name/Scheme ALTERITY THERAPEUTICS LTD ACN/ARSN/ABN 37 080 699 065 1. Details of substantial holder (1) Name JPMorgan Chase & Co. and i

Exhibit 99.1 605 Page 1 of 2 Form 605 Corporations Act 2001 Section 671B Notice of ceasing to be a substantial holder To Company Name/Scheme ALTERITY THERAPEUTICS LTD ACN/ARSN/ABN 37 080 699 065 1. Details of substantial holder (1) Name JPMorgan Chase & Co. and its affiliates ACN/ARSN (if applicable) NA 2. Changes in relevant interests Particulars of each change in, or change in the nature of, a r

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

Announcement Summary

Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Friday March 14, 2025 The +securities to be quoted are: +Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted Total number of

Form 603 Corporations Act 2001 Section Notice of initial substantial holder

Exhibit 99.1 Form 603 Corporations Act 2001 Section 671B Notice of initial substantial holder To Company Name/Scheme ALTERITY THERAPEUTICS LTD ACN/ARSN/ABN 37 080 699 065 1. Details of substantial holder (1) Name JPMorgan Chase & Co. and its affiliates ACN/ARSN (if applicable) NA The holder became a substantial holder on 11/March/2025 2. Details of voting power The total number of votes attached t

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Alterity Therapeutics Limited (Name of Regist

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the regi

NOTICE OF EXTRAORDINARY GENERAL MEETING/PROXY FORM

Exhibit 99.1

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Reg

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the r

Alterity Therapeutics Limited ABN 37 080 699 065 Interim financial report for the half-year ended 31 December 2024

Exhibit 99.1 Alterity Therapeutics Limited Appendix 4D Half-year ended 31 December 2024 Name of entity: Alterity Therapeutics Limited ABN: 37 080 699 065 Half-year ended: 31 December 2024 Previous period: 31 December 2023 Results for announcement to the market A$ Revenue from ordinary activities Down 6.0 % to 111,299 Net loss after tax (from ordinary activities) for the period attributable to memb

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Reg

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the r

Announcement Summary

Exhibit 99.1 Appendix 3B - Proposed issue of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement 24/2/2025 The Proposed issue is: A placement or other type of issue Total number of +securities proposed to be issued for a placement or other type of issue ASX +security code +Security description Maximum Number of +sec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Reg

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the r

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Reg

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the r

Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder

Exhibit 99.1 Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder To Company Name/Scheme Alterity Therapeutics Limited ACN/ARSN 080 699 065 1. Details of substantial holder (1) Name The Bank of New York Mellon Corporation (BNYMC) and each Group Entity listed in Annexure A (Group Entity),(together BNYMC Group) ACN/ARSN (if applicable) There was a change in

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Reg

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the r

Notice Under Section 708A(5)(e) of the Corporations Act

Exhibit 99.1 ASX ANNOUNCEMENT 17 February 2025 Notice Under Section 708A(5)(e) of the Corporations Act This notice is given by Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act). Details of securities issued Type: Shares Class/Description: Fully paid ordinary shares ASX

Total number of +securities on issue

Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Monday February 17, 2025 The +securities to be quoted are: +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Total number of +securities to be quo

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Reg

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the r

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Reg

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the r

Announcement Summary

Exhibit 99.1 Appendix 3B - Proposed issue of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement 10/2/2025 The Proposed issue is: A placement or other type of issue Total number of +securities proposed to be issued for a placement or other type of issue ASX +security code +Security description Maximum Number of +sec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Reg

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the r

Alterity Therapeutics Raises A$40.0 million in Placement – Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders – – Capital raising was strongly supported by domestic and international institutional investors –

Exhibit 99.1 Alterity Therapeutics Raises A$40.0 million in Placement – Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders – – Capital raising was strongly supported by domestic and international institutional investors – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 10 February 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or the “Company”), a

Form 603 Corporations Act 2001 Section Notice of initial substantial holder

Exhibit 99.1 Form 603 Corporations Act 2001 Section 671B Notice of initial substantial holder To Company Name/Scheme Alterity Therapeutics ltd ACN/ARSN/ABN 37 080 699 065 1. Details of substantial holder (1) Name JPMorgan Chase & Co. and its affiliates ACN/ARSN (if applicable) NA The holder became a substantial holder on 03/February/2025 2. Details of voting power The total number of votes attache

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Reg

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the r

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Reg

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the r

Alterity Therapeutics Limited Level 3, 460 Bourke Street, Melbourne, VIC 3000 Australia T: +61 (0)3 9349 4906 | WWW.alteritytherapeutics.com

Exhibit 99.1 Market Announcement 6 February 2025 Alterity Therapeutics Limited (ASX: ATH) – Trading Halt Description The securities of Alterity Therapeutics Limited (‘ATH’) will be placed in trading halt at the request of ATH, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Mon

Disclosure under Takeovers Panel Guidance Note 20: Equity Derivatives

Exhibit 99.1 ASX ANNOUNCEMENT 05 February 2025 Disclosure under Takeovers Panel Guidance Note 20: Equity Derivatives Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) (“the Company”) advises that it has received the attached notice from Point72 Associates, LLC which was provided to the Company pursuant to the Australian Takeovers Panel Guidance Note 20 – Equity Derivatives. Au

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Reg

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the r

Notice Under Section 708A(5)(e) of the Corporations Act

Exhibit 99.1 ASX ANNOUNCEMENT 04 February 2025 Notice Under Section 708A(5)(e) of the Corporations Act This notice is given by Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act). Details of securities issued Type: Shares Class/Description: Fully paid ordinary shares ASX

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Reg

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the r

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Alterity Therapeutics Limited (Name of Regi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the re

Total number of +securities on issue

Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement Thursday January 30, 2025 The +securities to be quoted are: +Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted Total number

ATH434 - 201 Phase 2 Topline Results January 30, 2025 Forward Looking Statements This presentation may contain some statements that may be considered “Forward - Looking Statements”, within the meaning of the US Securities Laws . Thus, any forward - l

Exhibit 99.1 ATH434 - 201 Phase 2 Topline Results January 30, 2025 Forward Looking Statements This presentation may contain some statements that may be considered “Forward - Looking Statements”, within the meaning of the US Securities Laws . Thus, any forward - looking statement relating to financial projections or other statements relating to the Company’s plans, objectives, expectations or inten

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Alterity Therapeutics Limited (Name of Regi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the re

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Alterity Therapeutics Limited (Name of Regi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the re

Alterity Therapeutics Limited Level 3, 460 Bourke Street, Melbourne, VIC 3000 Australia T: +61 (0)3 9349 4906 | WWW.alteritytherapeutics.com

Exhibit 99.1 Market Announcement 28 January 2025 Alterity Therapeutics Limited (ASX: ATH) – Trading Halt Description The securities of Alterity Therapeutics Limited (‘ATH’) will be placed in trading halt at the request of ATH, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thu

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Exhibit 99.1 Appendix 4C – Q2 FY25 Quarterly Cash Flow Report Highlights ● Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February 2025 ● ATH434-201 trial in early-stage MSA completed in November 2024 ● Positive interim data presented at MDS from the ATH434-202 Phase 2 trial in advanced MSA ● Multiple data presentations and public

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Alterity Therapeutics Limited (Name of Regi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the re

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Alterity Therapeutics Limited (Name of Regi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the re